Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-3, 5, 8, 11 and 21-26 of D. Leitch et al., US 18/271,800 (Jan. 11, 2022) are pending. Claims 21-26, to non-elected Groups (II)-(V) are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to non-elected inventions. Claims 1-3, 5, 8, 11 are under examination on the merits. Claims 1-3, 5, 8, 11 are rejected.
Restriction
During a telephone conversation with Johanna Schwartz on February 25, 2026, a provisional election was made without traverse to prosecute the invention of Group (I), claims 1-5 and 8-11. Claims 12-16 and 21-26, to non-elected Groups (II)-(V) are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to non-elected inventions. Applicant confirms the election in the Reply filed on September 4, 2026, and the restriction is made FINAL.
Withdrawal Rejections 35 U.S.C. 112(b)
Rejection of claims 5 and 10 under 35 U.S.C. 112(b) as being indefinite is withdrawn in view of Applicant’s amendment to claim 5 and cancellation of claim 10.
Withdrawal Claim Rejections - 35 USC § 102 (AIA )
Rejection of claims under 35 U.S.C. 102(a)(1) as being anticipated by M. van Laren et al., 38 Angewandte Chemie International Edition, 3715-3717 (1999) (“van Laren”) is withdrawn in view of Applicant’s amendment.
Rejection of claims under 35 U.S.C. 102(a)(1) as being anticipated by R. van Asselt et al., 33 Inorganic Chemistry, 1521-1531 (1994) (“van Asselt”) is withdrawn in view of Applicant’s amendment.
Rejection of claims under 35 U.S.C. 102(a)(1) as being anticipated by B. Crociani et al., Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry, 71-79 (1991) (“Crociani”) is withdrawn in view of Applicant’s amendment.
Claim Rejections 35 U.S.C. 112(a) -- New Matter
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
Amendments narrowing the claims by introducing elements or limitations which are not supported by the as-filed disclosure is a violation of the written description requirement of 35 U.S.C. 112(a). MPEP § 2163.05(II). The PTO has the initial burden of burden of making a prima facie case under § 112(a). MPEP § 2163.04. However, with respect to newly added or amended claims, applicant should show support in the original disclosure for the new or amended claims. MPEP § 2163(II)(A) (citing Hyatt v. Dudas, 492 F.3d 1365, 1370, n.4, 83 USPQ2d 1373, 1376, n.4 (Fed. Cir. 2007). Ipsis verbis disclosure is not necessary to satisfy the written description requirement; if a skilled artisan would have understood the inventor to be in possession of the claimed invention at the time of filing, even if every nuance of the claims is not explicitly described in the specification, then the adequate description requirement is met. MPEP § 2163(II)(A)(3)(a) (citing Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1560, 19 USPQ2d 1111, 1114 (Fed. Cir. 1991). Whether a description of a genus provides an adequate description of a later claimed subgenus is determined by reference to “blaze marks” in the originally filed disclosure. MPEP § 2163.05(II); Purdue Pharma LP v. Faulding Inc., 230 F.3d 1320, 1326 (Fed. Cir. 2000) (citing In re Ruschig, 392 F.2d 990, 994-95 (CCPA 1967); Fujikawa v. Wattanasin, 93 F.3d 1559, 1570-71 (Fed. Cir. 1996); cf. Ex parte Sorenson, 3 USPQ2d 1462 (Bd. Pat. App. & Inter. 1987).
35 U.S.C. 112(a) Rejection of Claim 1-3, 5, and 8
Claims 1-3, 5, and 8 are rejected under 35 U.S.C. 112(a) as failing to comply with the written description requirement on the grounds that these claims add new matter to independent claim 1 not present in the application as filed:
Claim 1 . . . provided that if R5 and/or R6 is heteroaliphatic or an organic functional group and the heteroaliphatic or organic functional group is a methoxy group, then
the methoxy group is located at an ortho position relative to the N-bearing carbon atom of the phenyl ring to which R5 and/or R6 are bound.
Applicant has not pointed out where this amendment is supported, nor can the Examiner find support for this claim limitation in the application as filed. Therefore, a prima facie case of new matter is established. MPEP § 2163(II)(A).1
The most relevant portion of the specification teaches:
In representative embodiments, each of the B and B' rings is phenyl, each of m and m' is 2 and each R5 and each R6 are each methyl or isopropyl. In some such embodiments, the two methyl or two isopropyl groups are bound to the phenyl ring at the ortho positions.
Specification at page 17, last four lines. This specification portion clearly does not support the subject claim limitation, at least, because as it makes no mention of “methoxy”.
Here, the subject claim amendment, to a subgenus, is not supported by the application as filed because there are no blaze marks in the original disclosure permitting one of skill to conclude that Applicant was in possession of the newly claimed subgenus. Whether a description of a genus provides an adequate description of a later claimed subgenus is determined by reference to “blaze marks” in the originally filed disclosure. MPEP § 2163.05(II); Purdue Pharma LP v. Faulding Inc., 230 F.3d 1320, 1326 (Fed. Cir. 2000) (citing In re Ruschig, 392 F.2d 990, 994-95 (CCPA 1967); Fujikawa v. Wattanasin, 93 F.3d 1559, 1570-71 (Fed. Cir. 1996); cf. Ex parte Sorenson, 3 USPQ2d 1462 (Bd. Pat. App. & Inter. 1987).
Claim Rejections - 35 USC § 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
§ 112(d) Rejection of Claim 11
Claim 11 is rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. See MPEP § 608.01(n)(III).
Claim 11 (dependent upon claim 1) claims structures that do not fall within the scope of claim 1, for example, the following structures:
PNG
media_image1.png
200
400
media_image1.png
Greyscale
At least these two compounds do not fall within the scope of base claim 1 because claim 1 does not permit substituents on the -N=CH-CH=N- portion of claimed Formula IIID. As such, claim 11 is broader than claim 1 in this respect and fails to further limit claim 1.
Applicant may cancel claim 11, amend claim 11 to proper dependent form, rewrite claim 11 in independent form, or present a sufficient showing that claim 11 complies with the statutory requirements.
Claim Rejections - 35 USC § 102 (AIA )
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
§ 102(a)(1) Rejection over O. Piechaczyk et al., 128 Journal of the American Chemical Society, 14306-14317 (2006) (“Piechaczyk”)
Claims 1, 5, 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by O. Piechaczyk et al., 128 Journal of the American Chemical Society, 14306-14317 (2006) (“Piechaczyk”). Reference Piechaczyk discloses the following palladium complex 2br:
PNG
media_image2.png
200
400
media_image2.png
Greyscale
This compound meets every chemical structure limitation of claim 1. The MeH2N+(CH2)- group is an electron withdrawing group. See specification at page 10, [064] (stating that “a quaternary amine” is an electron withdrawing group).2 Thus, the following claim 1 structure alternative is thus met:
Claim 1 . . . each of R1, R2, R3, and R4 independently is selected from hydrogen, aliphatic, aromatic, or an electron-withdrawing group provided that at least one of R1, R2, R3, or R4 is hydrogen the electron-withdrawing group . . .
The further limitations of claims 5 and 8 are clearly met.
Maintained Non-Statutory Double Patenting Rejections
The non-statutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A non-statutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
Provisional Non-Statutory Double Patenting Rejection over D. Leitch et al., US 18/838,903 (2023), published as US 2025/0153157 (2025)
Claims 1-3, 5, 8, 11 are provisionally rejected on the ground of non-statutory double patenting as being unpatentable over conflicting claim 16 of D. Leitch et al., US 18/838,903 (2023), published as US 2025/0153157 (2025). The rejection is provisional because the conflicting claims have not been patented. Conflicting claim 16 depicts palladium complex DMFDAB-Pd-MAH:
PNG
media_image3.png
200
400
media_image3.png
Greyscale
Instant claims 1-5, 8, and 10-11 are patentably indistinct from conflicting claim 16 because palladium complex DMFDAB-Pd-MAH anticipates the instant claims. Complex DMFDAB-Pd-MAH is the first listed species of instant claim 11.
Applicant’s Argument
Applicant requests that this rejection be held in abeyance until claims are allowed in the pending application or in the '903 application.
Terminal Disclaimer
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Subject Matter Free of the Art of Record
Subject to the new matter and double patenting rejections, claims 2, 3 and 11 are free of the art of record. The closest art of record is R. van Asselt et al., 33 Inorganic Chemistry, 1521-1531 (1994) (“van Asselt”).
R. van Asselt et al., 33 Inorganic Chemistry, 1521-1531 (1994) (“van Asselt”)
Reference van Asselt discloses zero valent bis(arylimino)acenaphthene (Ar-BIAN) and bis(phenylimino)camphane (Ph-BIC) palladium complexes. van Asselt at Abstract; see also, list of palladium complexes indexed from the reference by CAS in CAS Abstract and Indexed Compounds, R. van Asselt et al., 33 Inorganic Chemistry, 1521-1531 (1994). Reference van Asselt discloses that these palladium complexes are efficient catalysts for homogeneous hydrogenation and carbon-carbon cross-coupling reactions. van Asselt at page 1522, col. 1. The two structurally closest van Asselt compounds are the following Pd(2,6-iPr₂C₆H₃-BIAN)(MA) (5c) and Pd(Ph-BIC)(MA) (9c) complexes:
PNG
media_image4.png
200
400
media_image4.png
Greyscale
See, van Asselt at page 1524, Scheme at top of col. 1.
Compare the above van Asselt compounds to the following claim 11, 23rd and 24th listed compounds:
PNG
media_image5.png
200
400
media_image5.png
Greyscale
Differences between van Asselt and the Claims
The van Asselt compounds differs from claims 2 and 3 in that these claims (per base claim 1) not permit substituents on the di-nitrogen containing ring. Respecting claim 11, the above two structurally closest van Asselt compounds (5c) and (9c) respectively differ from the 23rd and 24th listed compounds in at least alkyl substitutions of the phenyl rings (where the claim 11, 23rd listed compound has additional structural differences from prior art compound (5c)). Claim 11 is discussed here in view of the § 112(d) rejection.
Obviousness of a claimed compound can also be supported where there is motivation to substitute particular chemical moieties in a prior art compound for others so as to arrive at a claimed compound. MPEP § 2143(I)(B). For example, in the chemical arts, the rationale is stated as motivation to select a known compound and also motivation to structurally modify the selected compound in a particular way to achieve a claimed compound. MPEP § 2143(I)(B) (see for example, MPEP § 2143(I)(B) Example 9, citing Eisai Co. Ltd. v. Dr. Reddy’s Labs., Ltd., 533 F.3d 1353, 87 USPQ2d 1452 (Fed. Cir. 2008).
Claims 2, 3 and 11 Are not Obvious in view of van Asselt
Claims 2, 3 and 11 are not obvious in view of the cited closest van Asselt compounds, at least because motivation is lacking to make the required structural modifications so as to arrive at a claimed compound. MPEP § 2143(I)(B).
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEXANDER R PAGANO whose telephone number is (571)270-3764. The examiner can normally be reached 8:00 AM through 5:00 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
ALEXANDER R. PAGANO
Examiner
Art Unit 1692
/ALEXANDER R PAGANO/Primary Examiner, Art Unit 1692
1 With respect to newly added or amended claims, applicant should point out support in the original disclosure for the new or amended claims. MPEP § 2163(II)(A) (citing Hyatt v. Dudas, 492 F.3d 1365, 1370, n.4, 83 USPQ2d 1373, 1376, n.4 (Fed. Cir. 2007) (citing MPEP § 2163.04 which provides that a "simple statement such as ‘applicant has not pointed out where the new (or amended) claim is supported, nor does there appear to be a written description [for the subject limitation] in the application as filed’ may be sufficient where the claim is a new or amended claim, the support for the limitation is not apparent, and applicant has not pointed out where the limitation is supported"); see also MPEP §§ 714.02 and 2163.06 ("Applicant should ... specifically point out the support for any amendments made to the disclosure.").
2 An alkyl group alone is electron withdrawing, as well as an alkyl group substituted with an amine (e.g., MeNHCH2-). See e.g., L. Salvatella et al., 102 Journal of Chemical Education, 4666-4675 (2025) (see page 4668, col. 1 stating (“[t]he slight electron-withdrawing character of methyl groups observed in alkanes is reinforced when bonded to heteroatoms . . . [t]he enhanced electron-withdrawing character of methyl groups in amines is partly due to nN → σC−H* hyperconjugation”). Post-filing date evidence can be relied on to show the properties inherent in a prior art product. See In re Wilson, 311 F.2d 266, 268–69 (CCPA 1962).